Midatech Pharma PLC (LON: MTPH; NASDAQ:MTP) said it had received the regulatory green light for a trial that may eventually pave the way for its long-acting drug to be administered by patients at home.
MTD201 has already negotiated a phase I study which showed it to have significant advantages over Novartis' Sandostatin LAR, the current standard of care.
The treatment is being developed for people suffering acromegaly, where the body produces too much growth hormone, and neuroendocrine tumours, which affect hormone-releasing cells and can sometimes be cancerous.
The point of the additional trial is to assess the delivery mechanism.
Midatech wants to see whether it is clinically effective administering MTD201 via a subcutaneous injection, which means going into a layer of the skin rather than muscle.
Using this method would reduce the pain of the jab and “allow the potential for self-administration at home without the need to for hospital visits to receive drug injections”.
Data from the trial on 28 healthy people will be available towards the end of the year, or early 2020, ahead of the pivotal registration study next year.
MTD201 incorporates the company’s Q-Sphera sustained release technology.